



Revista Latinoamericana de Hipertensión

ISSN: 1856-4550

latinoamericanadehipertension@gmail.com

Sociedad Latinoamericana de Hipertensión

Organismo Internacional

López-Jaramillo, P.; Herrera, J. A.; Arenas-Mantillaa, M.; Jáuregui, I. E.; Mendoza, M. A.

Subclinical infection as cause of inflammation in preeclampsia

Revista Latinoamericana de Hipertensión, vol. 2, núm. 3, mayo-junio, 2007, pp. 98-101

Sociedad Latinoamericana de Hipertensión

Caracas, Organismo Internacional

Available in: <http://www.redalyc.org/articulo.oa?id=170216980007>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative

Subclinical infection as cause of inflammation in preeclampsia

P. López-Jaramillo^{a,b}, J.A. Herrera,

M. Arenas-Mantilla^a, I.E. Jáuregui^a, M.A. Mendoza,

^a VILANO GROUP, Research Institute, Cardiovascular Foundation of Colombia, Floridablanca, Santander, Colombia.

^b Research Direction, Medical School, Universidad de Santander (UDES), Bucaramanga, Santander, Colombia.

^c Department of Family Medicine, School of Medicine, Universidad del Valle, Cali, Valle del Cauca, Colombia.

Keywords: Preeclampsia, inflammation, infection, endothelium, nitric oxide **Word count:** Abstract: 216; Manuscript: 1482

Correspondence and request for reprints: Patricio López-Jaramillo, MD, PhD.

Instituto de Investigaciones, Fundación Cardiovascular de Colombia. Calle 155* # 23-58, 3rd Floor.

Floridablanca, Santander, Colombia Tel: 577-6399292. Ext.331-343. Fax: 577-6392744.

E mail: joselopez@fcv.org, jplopezj@hotmail.com

Recibido: 22/02/2007

Aceptado: 23/04/2007

Abstract

Preeclampsia, a pregnancy-exclusive hypertensive disorder, is the major cause of maternal and perinatal mortality, with a greater importance in developing countries. The role of inflammation in the pathogenesis of preeclampsia has been the object of recent studies by our group. We have described elevated levels of inflammatory markers (TNF α , IL6 and CRP) in preeclamptic patients and demonstrated that Latin-American women present a higher degree of inflammation than women from developed countries. We have results that suggest that chronic subclinical infections and insulin resistance are the most probable causes of the increased inflammation in preeclampsia. Moreover, we showed that early treatment of urinary and vaginal infections decreased the incidence of preeclampsia. We also have evidences that suggest that inflammation leads to endothelial dysfunction, predisposing women to develop preeclampsia. Increased levels of inflammation markers and endothelial dysfunction are found in the early stages of pregnancy in women who later on develop preeclampsia. Appropriate prenatal care programs, including screening and treatment of urinary, vaginal and periodontal infections in early pregnancy and prevention of factors that predispose to insulin resistance, as excessive weight gain during pregnancy, may reduce the incidence of preeclampsia in Latin-American women.

Introduction

Hyertensive disorders during pregnancy are the principal cause of maternal and perinatal morbidity and mortality, preeclampsia (PE) being the most important among these alterations^{1,2}. The etiology of PE comprises multiple risk factors^{3,4}, and we have proposed that the impact of each of them varies with the populations, with considerable differences between developed and developing countries⁵. In Latin-America, inappropriate nutrition, young maternal age and inadequate prenatal care programs, are important risk factors in the development of PE. In these countries, PE is the main cause of maternal mortality, which is 10 to 20 fold higher than in developed countries^{2,5,6}.

Excessive inflammation and risk of preeclampsia

Healthy pregnant women present a certain degree of inflammation, due in part to the activation of the immune system induced by the fetal allograft⁷. However, preeclamptic women have an excessive inflammatory response as demonstrated by increased concentrations of proinflammatory cytokines⁸. The role of these cytokines in normal pregnancy is not entirely understood. Some of them have been related to the mechanisms involved in the initiation and maintenance of gestation. For instance, TNF- α seems to regulate invasion and growth of the trophoblast into maternal spiral arteries⁷. However, women who

developed PE have significantly higher levels of TNF- α , IL2 and IL6^{8,12}.

In Andean population¹³, we have confirmed the increased concentrations of proinflammatory cytokines in women with PE and demonstrated that our normal pregnant women have significantly higher concentrations of CRP, TNF- α and IL6, than those reported in studies conducted in pregnant women from developed countries^{10,12,14}.

The relationship of sub-clinical infection with preeclampsia

Asymptomatic bacteriuria is more frequently diagnosed in pregnant women with PE^{15,16}. Various studies have described that urinary infection is associated with the development of preeclampsia, and that this association is more frequent among primigravidae women^{17,18}. We have demonstrated that the early diagnosis and treatment of urinary and vaginal infections decreased the incidence of PE by 64 %¹⁹.

Chronic subclinical infection **appears as a factor that** alters the endothelial production of nitric oxide (NO), substance which maintains a basal vessel dilator tone in the cardiovascular system^{20,21}. An increased oxidative stress produced by infection impairs the bioactivity of NO and leads to endothelial dysfunction, event that is crucial in the development of PE^{4,22}. In support of this view, PE-like manifestations have been induced in experimental models by blocking endothelial production of NO^{20,23}. Moreover, in a randomized, double-blind, placebo controlled clinical trial, we included primigravidae women with family history of PE and abnormal Doppler ultrasound in uterine or arcuate arteries (diastolic notch). Women received daily elemental calcium and conjugated linoleic acid or lactose–starch placebo^{24,25}. Endothelial function was evaluated by flow mediated dilation (FMD), method that has been validated in our population^{26, 27}. Moreover, all women were screened for urinary and vaginal infections. The frequency of endothelial dysfunction was significantly higher among women with these infections and the antibiotic therapy improved FMD and decreased the risk of PE^{24,25}. Recently, we established a cohort of 506 Colombian pregnant women with known risk factors for PE. FMD was realized in all women at 16 weeks of gestation and blood samples were withdrawn. All women were followed until delivery, 32 who developed PIH (Pregnancy induced hypertension) and 64 controls matched by body mass index and maternal and gestational age, were included in a nested case-control study²⁸. CRP concentration and leukocyte counts were higher and FMD was lower in the women who developed PIH, suggesting that inflammation and endothelial dysfunction early in pregnancy precede the appearance of the clinical manifestations of PE. Furthermore, a correla-

tion between the degree of inflammation and the severity of the hypertensive disorder was observed²⁸. On the basis of these results we have suggested that inflammation secondary to chronic subclinical infection increases the risk of PIH¹⁹.

Periodontal infection and risk of preeclampsia

Several studies have demonstrated a relationship between periodontitis and increased risk of PE, preterm delivery and low birth weight²⁹⁻³¹. In Colombia we have reported³² that chronic periodontal disease was more frequent in women with PE than in healthy pregnant controls (63.8% vs 36.6%), with a significant association between PE and chronic periodontitis (OR: 3.0; 95%-CI: 1.91-4.87). Two red complex microorganisms, *Porphyromonas gingivalis* and *Tannerella forsythensis*, and the green complex microorganism *Eikenella corrodens* were more frequently isolated in women with PE. These pathogens have also been isolated in atherosclerotic plaques in humans with coronary artery disease³³. Moreover, we assessed the periodontal state and the CRP concentrations in 145 preeclamptic and 253 healthy pregnant controls³⁴. Women with PE had a higher frequency of chronic periodontal disease (59% vs 36%; $p < 0.001$) and in these women the CRP concentrations increased progressively depending on the severity of the periodontal disease. The CRP levels were significantly higher in the moderate/severe periodontitis group of women with PE [0.01]. Additionally *P. gingivalis* and *E. corrodens* were isolated more frequently in preeclamptic women³⁴. These studies demonstrate a significant association between chronic periodontitis and PE, and suggest that the systemic inflammation observed in women that developed PE could be the result of periodontal infection.

Conclusión

Preeclampsia is the most important cause of maternal mortality in developing countries. Among the several conditions identified as risk factors for PE, sub-clinical infections have a major role in Latin-American population. Chronic inflammation induced by periodontal, vaginal and/or urinary infections causes endothelial dysfunction, a crucial alteration in the pathophysiology of PE. Early diagnosis and treatment of asymptomatic urinary and vaginal infections have been demonstrated to be an effective strategy to reduce the incidence of PE. Screening and treatment of common sub-clinical infections must be incorporated to the prenatal care programs, if we want to obtain a considerable reduction in maternal and perinatal mortality due to PE.

Acknowledgements

To the Colombian Institute for Science and Technology Development "Colciencias" (Grant No 6566-04-18061). The authors would like to thank Jean Noël Guillemot for his assistance in preparing the manuscript.

References

1. Walker JJ: Pre-eclampsia. *Lancet* 2000; 356:1260-1265.
2. Maternal mortality in 2000: estimates developed by WHO, UNICEF and UNFPA. World Health Organization 2004.
3. López-Jaramillo P: Calcium, nitric oxide, and preeclampsia. *Sem Perinatol* 2000; 24: 33-36.
4. López-Jaramillo P, Casas JP, Serrano NC: Preeclampsia: from epidemiological observations to molecular mechanisms. *Braz J Med Biol Res* 2001; 34: 1227-1235.
5. López-Jaramillo P, García RG, López M: Preventing pregnancy-induced hypertension: are there regional differences for this global problem? *J Hypertens* 2005; 23: 1121-1129.
6. WHO. Technical Report Series. The hypertensive disorders of pregnancy. Geneva, 1987.
7. Kupfermanc MJ, Peaceman AM, Wington TR, Tamura RK, Rehnberg KA, Socol ML: Immunoreactive tumor necrosis factor- α is elevated in maternal plasma but undetected in amniotic fluid in the second trimester. *Am J Obstet Gynecol* 1994; 171: 976-979.
8. Redman C, Sacks G, Sargent I: Preeclampsia: An excessive maternal inflammatory response to pregnancy. *Am J Obstet Gynecol* 1990; 180: 499-506.
9. López-Jaramillo P, Escudero C, Moya W: Markers of systemic inflammation and nitric oxide metabolites in preeclampsia. *Nitric Oxide Biol Chem* 1998; 2: 127.
10. Vince GS, Starkey PM, Austgulen R: Interleukin-6, tumor necrosis factor and soluble receptors in women with preeclampsia. *Br J Obstet Gynaecol* 1995; 102: 20-25.
11. Hamai Y, Fujii T, Yamashita T, Nishina H, Kozuma S, Mikami Y, et al: Evidence for elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. *Am J Reprod Immunol* 1997; 38: 89-93.
12. Kupfermanc MJ, Peaceman AM, Aderka D, Wallach D, Socol ML: Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia. *Obstet Gynecol* 1996; 88: 420-427.
13. Teran E, Escudero C, Moya W, Flores M, Vallance P, López-Jaramillo P: Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with preeclampsia. *Int J Gynecol Obstet* 2001; 75:243-249.
14. Greer IA, Lyall F, Perera T, Boswell F, Macara LM: Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? *Obstet Gynecol* 1994; 84: 937-940.
15. Hill JA, Devoe L, Bryans C: Frequency of asymptomatic bacteriuria in preeclampsia. *Obstet Gynecol* 1986; 67: 529-532.
16. Abi Said D, Annegers JF, Combs-Cantrell D, Frankowski RF, Willmore LJ: Case-control study of the risk factors for preeclampsia. *Am J Epidemiol* 1995; 142: 437-441.
17. Hsu CD, Witter FR: Urogenital infection in preeclampsia. *Int J Gynecol Obstet* 1995; 49: 271-275.
18. Mittendorf R, Lain KY, Williams MA, Walker CK: Preeclampsia. A nested, case-control study for risk factors and their interactions. *J Reprod Med* 1996; 41: 491-496.
19. Herrera JA, Chaudhuri G, López-Jaramillo P: Is infection a major risk factor for preeclampsia? *Medical Hypotheses* 2001; 57: 393-397.
20. Yallampalli C, Garfield RE: Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. *Am J Obstet Gynecol* 1993; 169: 1316-1320.
21. Moncada S, Higgs EA, Hodson HF, Knowles RG, López-Jaramillo P, McCall T, et al: The L-arginine:nitric oxide pathway. *J Cardiovasc Pharmacol* 1991; 17(Suppl 3): S1-S9.
22. Davidge ST: Oxidative stress and altered endothelial cell function in preeclampsia. *Semin Reprod Endocrinol* 1998; 16: 65-73.
23. Belayet HM, Kanayama N, Kathun S, El Maradny E, Masui M, Tokunaga N, et al: Decreased renal and hepatic blood flow with preeclampsia-like histologic changes was obtained by stimulation of the celiac ganglion with LPS. *Am J Perinatol* 1998; 15: 109-114.
24. Herrera JA, Shahabuddin AK, Ersheng G, Wei Y, García RG, López-Jaramillo P: Calcium plus linoleic acid therapy for pregnancy-induced hypertension. *Int J Gynecol Obstet* 2005; 91: 221-227.
25. Herrera JA, Arevalo-Herrera M, Shahabuddin AK, Ersheng G, Herrera S, García RG, et al: Calcium and conjugated linoleic acid reduces pregnancy-induced hypertension and decreases intracellular calcium in lymphocytes. *Am J Hypertens* 2006; 19: 381-387.
26. Sierra-Laguado J, García RG, López-Jaramillo P: Flow-mediated dilation of the brachial artery in pregnancy. *Int J Gynecol Obstet* 2006; 93: 60-61.
27. Accini JL, Sotomayor A, Trujillo F, Barrera JG, Bautista L, López-Jaramillo P: Colombian study to assess the use of noninvasive determination of endothelium-mediated vasodilatation (CANDEV). Normal values and factors associated. *Endothelium* 2001; 8: 157-166.
28. García RG, Celedón J, Sierra-Laguado J, Alarcón MA, Luengas C, Silva F, et al: Raised C-reactive protein and impaired flow medi-

ated vasodilation precede the development of preeclampsia. *Am J Hypertens* 2007; 20:437-442.

29. Offenbacher S, Katz V, Fertik G, Collins J, Boyd D, Maynor G, McKaig R, Beck J. Periodontal infection as a possible risk factor for preterm low birth weight. *J Periodontol.* 1996;67:1103-1113.
30. Boggess KA, Lieff S, Murtha AP, Moss K, Beck J, Offenbacher S: Maternal periodontal disease is associated with an increased risk for preeclampsia. *Obstet Gynecol* 2003; 101: 227-231.
31. Canakci V, Canakci CF, Canakci H, Canakci E, Cicek Y, Ingec M, et al: Periodontal disease as a risk factor for pre-eclampsia: a case control study. *Aust N Z J Obstet Gynaecol* 2004; 44: 568-573.
32. Contreras A, Herrera JA, Soto JE, Arce RM, Jaramillo A, Botero JE: Periodontitis is associated with preeclampsia in pregnant women. *J Periodontol* 2006; 77: 182-188.
33. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ: Identification of periodontal pathogens in atheromatous plaques. *J Periodontol* 2000; 71: 1554-1560.
34. Herrera JA, Parra B, Herrera E, Botero JE, Arce RM, Contreras A, et al. Periodontal disease severity is related to high levels of C-reactive protein in Preeclampsia. *J Hypertens* 2007; in press.